دورية أكاديمية
Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma:updated data with mivavotinib (TAK-659/CB-659)
| العنوان: | Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma:updated data with mivavotinib (TAK-659/CB-659) |
|---|---|
| المؤلفون: | Gordon, Leo I, Karmali, Reem, Kaplan, Jason B, Popat, Rakesh, Burris, Howard A, Ferrari, Silvia, Madan, Sumit, Patel, Manish R, Gritti, Giuseppe, El-Sharkawi, Dima, Chau, F Ian, Radford, John, de Oteyza, Jaime Pérez, Zinzani, Pier Luigi, Iyer, Swaminathan P, Townsend, William, Miao, Harry, Proscurshim, Igor, Wang, Shining, Katyayan, Shilpi, Yuan, Ying, Zhu, Jiaxi, Stumpo, Kate, Shou, Yaping, Carpio, Cecilia, Bosch, Francesc |
| المصدر: | Gordon , L I , Karmali , R , Kaplan , J B , Popat , R , Burris , H A , Ferrari , S , Madan , S , Patel , M R , Gritti , G , El-Sharkawi , D , Chau , F I , Radford , J , de Oteyza , J P , Zinzani , P L , Iyer , S P , Townsend , W , Miao , H , Proscurshim , I , Wang , S , Katyayan , S , Yuan , Y , Zhu , J , Stumpo , .... |
| سنة النشر: | 2023 |
| المجموعة: | The University of Manchester: Research Explorer - Publications |
| مصطلحات موضوعية: | Humans, Vascular Endothelial Growth Factor Receptor-1, Treatment Outcome, Syk Kinase, Lymphoma, Large B-Cell, Diffuse/pathology, Protein Kinase Inhibitors/adverse effects, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, ResearchInstitutes_Networks_Beacons/mcrc, Manchester Cancer Research Centre |
| الوصف: | We report an updated analysis from a phase I study of the spleen tyrosine kinase (SYK) and FMS-like tyrosine kinase 3 inhibitor mivavotinib, presenting data for the overall cohort of lymphoma patients, and the subgroup of patients with diffuse large B-cell lymphoma (DLBCL; including an expanded cohort not included in the initial report). Patients with relapsed/refractory lymphoma for which no standard treatment was available received mivavotinib 60-120 mg once daily in 28-day cycles until disease progression/unacceptable toxicity. A total of 124 patients with lymphoma, including 89 with DLBCL, were enrolled. Overall response rates (ORR) in response-evaluable patients were 45% (43/95) and 38% (26/69), respectively. Median duration of response was 28.1 months overall and not reached in DLBCL responders. In subgroups with DLBCL of germinal center B-cell (GCB) and non-GCB origin, ORR was 28% (11/40) and 58% (7/12), respectively. Median progression free survival was 2.0 and 1.6 months in the lymphoma and DLBCL cohorts, respectively. Grade ≥3 treatment-emergent adverse events occurred in 96% of all lymphoma patients, many of which were limited to asymptomatic laboratory abnormalities; the most common were increased amylase (29%), neutropenia (27%), and hypophosphatemia (26%). These findings support SYK as a potential therapeutic target for the treatment of patients with B-cell lymphomas, including DLBCL. Trial registration: ClinicalTrials.gov number: NCT02000934. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.18632/oncotarget.28352 |
| الإتاحة: | https://doi.org/10.18632/oncotarget.28352Test https://research.manchester.ac.uk/en/publications/b8ae73bd-5dbe-461c-8359-f1a74f468894Test |
| حقوق: | info:eu-repo/semantics/openAccess |
| رقم الانضمام: | edsbas.549541B9 |
| قاعدة البيانات: | BASE |
| DOI: | 10.18632/oncotarget.28352 |
|---|